JP6240078B2 - 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール - Google Patents
肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール Download PDFInfo
- Publication number
- JP6240078B2 JP6240078B2 JP2014534680A JP2014534680A JP6240078B2 JP 6240078 B2 JP6240078 B2 JP 6240078B2 JP 2014534680 A JP2014534680 A JP 2014534680A JP 2014534680 A JP2014534680 A JP 2014534680A JP 6240078 B2 JP6240078 B2 JP 6240078B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- pyrimidin
- ylamino
- thiazole
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1ccncc1 Chemical compound *c1ccncc1 0.000 description 4
- ZPWUAVXLBCNQMC-UHFFFAOYSA-N CC(C)c1nc(ccc(C)c2)c2[s]1 Chemical compound CC(C)c1nc(ccc(C)c2)c2[s]1 ZPWUAVXLBCNQMC-UHFFFAOYSA-N 0.000 description 1
- KLTKELPBDAPNPA-UHFFFAOYSA-N CN(C)C(Nc(nc1)ncc1Br)=S Chemical compound CN(C)C(Nc(nc1)ncc1Br)=S KLTKELPBDAPNPA-UHFFFAOYSA-N 0.000 description 1
- AOPIPGKZJOHGOY-UHFFFAOYSA-N CNC(c1c(-c2ccccn2)nc(Nc2ncccn2)[s]1)=O Chemical compound CNC(c1c(-c2ccccn2)nc(Nc2ncccn2)[s]1)=O AOPIPGKZJOHGOY-UHFFFAOYSA-N 0.000 description 1
- XKLDNSGZKJWVRC-UHFFFAOYSA-N CN[IH]Cc1cc(-c2c[s]c(Nc3ncccn3)n2)ncc1 Chemical compound CN[IH]Cc1cc(-c2c[s]c(Nc3ncccn3)n2)ncc1 XKLDNSGZKJWVRC-UHFFFAOYSA-N 0.000 description 1
- JEAVIRYCMBDJIU-UHFFFAOYSA-N Cc1cccc(O)n1 Chemical compound Cc1cccc(O)n1 JEAVIRYCMBDJIU-UHFFFAOYSA-N 0.000 description 1
- DNPMOGQMEOPVNT-UHFFFAOYSA-N O=C(CBr)c1ncccc1 Chemical compound O=C(CBr)c1ncccc1 DNPMOGQMEOPVNT-UHFFFAOYSA-N 0.000 description 1
- JOWNSKXJCUZVAR-UHFFFAOYSA-N OC(c1c(-c2ccccn2)nc(Nc2ncccn2)[s]1)=O Chemical compound OC(c1c(-c2ccccn2)nc(Nc2ncccn2)[s]1)=O JOWNSKXJCUZVAR-UHFFFAOYSA-N 0.000 description 1
- QAINFPRHEISSOY-UHFFFAOYSA-N c1c(-c2ccccn2)nc(Nc2ncccn2)[s]1 Chemical compound c1c(-c2ccccn2)nc(Nc2ncccn2)[s]1 QAINFPRHEISSOY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542907P | 2011-10-04 | 2011-10-04 | |
| US61/542,907 | 2011-10-04 | ||
| PCT/US2012/058674 WO2013052613A1 (en) | 2011-10-04 | 2012-10-04 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079817A Division JP2017149753A (ja) | 2011-10-04 | 2017-04-13 | 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528450A JP2014528450A (ja) | 2014-10-27 |
| JP2014528450A5 JP2014528450A5 (enExample) | 2015-11-26 |
| JP6240078B2 true JP6240078B2 (ja) | 2017-11-29 |
Family
ID=48044139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534680A Expired - Fee Related JP6240078B2 (ja) | 2011-10-04 | 2012-10-04 | 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール |
| JP2017079817A Withdrawn JP2017149753A (ja) | 2011-10-04 | 2017-04-13 | 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079817A Withdrawn JP2017149753A (ja) | 2011-10-04 | 2017-04-13 | 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20140249154A1 (enExample) |
| EP (1) | EP2763674A4 (enExample) |
| JP (2) | JP6240078B2 (enExample) |
| KR (1) | KR20140071472A (enExample) |
| CN (1) | CN103957908A (enExample) |
| AU (1) | AU2012318670B2 (enExample) |
| BR (1) | BR112014007963A2 (enExample) |
| CA (1) | CA2850779A1 (enExample) |
| HK (1) | HK1200361A1 (enExample) |
| IL (1) | IL231923A0 (enExample) |
| PH (1) | PH12014500724A1 (enExample) |
| SG (1) | SG11201401207XA (enExample) |
| WO (1) | WO2013052613A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9582896B2 (en) * | 2011-09-02 | 2017-02-28 | Qualcomm Incorporated | Line tracking with automatic model initialization by graph matching and cycle detection |
| US9676765B2 (en) * | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
| WO2014159938A1 (en) | 2013-03-13 | 2014-10-02 | The Broad Institute, Inc. | Substituted aminothiazoles for the treatment of tuberculosis |
| SI2994465T1 (sl) | 2013-05-10 | 2018-10-30 | Karus Therapeutics Limited | Novi inhibitorji histon deacetilaze |
| US10442779B2 (en) | 2014-09-22 | 2019-10-15 | Fratagene Therapeutics S.R.L. | Compositions and methods for treating Friedreich's ataxia |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| WO2016176396A1 (en) * | 2015-04-29 | 2016-11-03 | Foresight Biotherapeutics, Inc. | Therapeutic combinations of antiviral and anti-inflammatory therapies |
| CN105524056A (zh) * | 2016-01-05 | 2016-04-27 | 中山大学肿瘤防治中心 | 一种氨基噻唑化合物及其制备方法和应用 |
| US10913734B2 (en) * | 2016-07-11 | 2021-02-09 | Baruch S. Blumberg Institute | Substituted aminothiazoles |
| IL271491B2 (en) * | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| US10426775B2 (en) | 2017-09-11 | 2019-10-01 | Fratagene Therapeutics Srl | Methods for treating Friedreich's ataxia with etravirine |
| WO2022087326A1 (en) * | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
| EP4746882A1 (en) | 2023-07-20 | 2026-05-27 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Inhibitors of smndc1 and their therapeutic use |
| WO2025151517A1 (en) * | 2024-01-08 | 2025-07-17 | Wavebreak Therapeutics Limited | Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2397661C (en) * | 2000-03-01 | 2012-01-03 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
| HUP0401748A3 (en) * | 2001-08-13 | 2011-03-28 | Janssen Pharmaceutica Nv | 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them |
| JP2007530696A (ja) * | 2004-03-30 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物 |
| US20050227989A1 (en) * | 2004-04-13 | 2005-10-13 | Icagen, Inc. | Polycyclic thiazoles as potassium ion channel modulators |
| AU2006244203B2 (en) * | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| NZ570835A (en) * | 2006-03-08 | 2011-11-25 | Achillion Pharmaceuticals Inc | Substituted aminothiazole derivatives with anti-HCV activity |
| WO2008083098A1 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| US20100248365A1 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
-
2012
- 2012-10-04 PH PH1/2014/500724A patent/PH12014500724A1/en unknown
- 2012-10-04 CA CA2850779A patent/CA2850779A1/en not_active Abandoned
- 2012-10-04 CN CN201280059490.1A patent/CN103957908A/zh active Pending
- 2012-10-04 SG SG11201401207XA patent/SG11201401207XA/en unknown
- 2012-10-04 AU AU2012318670A patent/AU2012318670B2/en not_active Ceased
- 2012-10-04 KR KR1020147011691A patent/KR20140071472A/ko not_active Ceased
- 2012-10-04 BR BR112014007963A patent/BR112014007963A2/pt not_active IP Right Cessation
- 2012-10-04 EP EP12838333.8A patent/EP2763674A4/en not_active Withdrawn
- 2012-10-04 US US14/349,014 patent/US20140249154A1/en not_active Abandoned
- 2012-10-04 HK HK15101053.5A patent/HK1200361A1/xx unknown
- 2012-10-04 WO PCT/US2012/058674 patent/WO2013052613A1/en not_active Ceased
- 2012-10-04 JP JP2014534680A patent/JP6240078B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-03 IL IL231923A patent/IL231923A0/en unknown
-
2016
- 2016-09-07 US US15/258,393 patent/US10087173B2/en not_active Expired - Fee Related
-
2017
- 2017-04-13 JP JP2017079817A patent/JP2017149753A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20140249154A1 (en) | 2014-09-04 |
| IL231923A0 (en) | 2014-05-28 |
| AU2012318670A1 (en) | 2014-05-22 |
| EP2763674A1 (en) | 2014-08-13 |
| WO2013052613A1 (en) | 2013-04-11 |
| SG11201401207XA (en) | 2014-05-29 |
| JP2017149753A (ja) | 2017-08-31 |
| HK1200361A1 (en) | 2015-08-07 |
| AU2012318670B2 (en) | 2017-09-07 |
| US10087173B2 (en) | 2018-10-02 |
| PH12014500724A1 (en) | 2014-05-19 |
| CA2850779A1 (en) | 2013-04-11 |
| KR20140071472A (ko) | 2014-06-11 |
| BR112014007963A2 (pt) | 2013-04-11 |
| CN103957908A (zh) | 2014-07-30 |
| US20170066758A1 (en) | 2017-03-09 |
| JP2014528450A (ja) | 2014-10-27 |
| EP2763674A4 (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017149753A (ja) | 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール | |
| US10669252B2 (en) | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | |
| AU2013226013B2 (en) | Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation and Their Method of Use | |
| US9949951B2 (en) | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | |
| JP5395844B2 (ja) | イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| US12595267B2 (en) | Preparation method for amide compound and application thereof in field of medicine | |
| JP5463592B2 (ja) | アデノシンａ１レセプターアンタゴニストとしての新規化合物 | |
| KR20180015255A (ko) | Hpk1 억제제 및 이의 사용 방법 | |
| JP2022532719A (ja) | Ａｃｓｓ２阻害剤およびその使用方法 | |
| JP2021503013A (ja) | Ａｃｓｓ２阻害剤およびその使用方法 | |
| KR20240095274A (ko) | 프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도 | |
| JP5910976B2 (ja) | 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物 | |
| KR20160138136A (ko) | 티에노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 백혈병 치료 및 예방용 약학 조성물 | |
| JP6454419B2 (ja) | 抗癌剤としての７−（モルホリニル）−２−（Ｎ−ピペラジニル）メチルチエノ［２，３−ｃ］ピリジン誘導体 | |
| US11834432B2 (en) | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | |
| KR101472944B1 (ko) | 2＇,2-비스티아졸 비뉴클레오시드 화합물, 이의 제조방법, 이를 포함하는 약학 조성물 및 이의 간염 바이러스 억제제로서의 용도 | |
| US10913734B2 (en) | Substituted aminothiazoles | |
| JP2024534208A (ja) | Ｐａｒｐ７阻害剤及びその使用 | |
| KR20260032992A (ko) | 지방산 결합 단백질(fabps) 억제제, 그 사용 방법, 및 제조 방법 | |
| KR20210024019A (ko) | 탄키라아제 저해제로서의 1,2,4-트리아졸 유도체 | |
| US20230084927A1 (en) | Glucose uptake inhibitors and uses thereof | |
| JP2008531688A (ja) | ガン化学療法薬として有用な１，３−チアゾール−５−カルボキシアミド | |
| WO2015054117A1 (en) | Functionalized furan-2-sulfonamides exhibiting endothelial lipase inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151005 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151005 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160421 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170413 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170915 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171010 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171102 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6240078 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |